EBV LMP-2A Antibody (4E11): sc-101316

EBV LMP-2A Antibody (4E11) is a rat monoclonal IgG1 antibody that detects EBV LMP-2A of Epstein-Barr virus (EBV) by western blotting (WB), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). EBV LMP-2A is a 497 amino acid protein that plays a crucial role in the survival and proliferation of EBV-infected cells, as EBV LMP-2A is expressed on the surface of these cells and is involved in critical signaling pathways. Notably, EBV LMP-2A interacts with protein tyrosine kinases, which leads to the activation of the phosphatidylinositol 3-kinase (PI3K) pathway, a key regulator of cell growth and survival. This interaction helps prevent apoptosis, allowing infected cells to evade normal cell death mechanisms and contributing to the development of EBV-associated malignancies. Furthermore, EBV LMP-2A can mimic B-cell receptor complex signaling in B-cell receptor-negative cells, underscoring EBV LMP-2A′s importance in the survival of mutated cells and potential role in tumorigenesis. Anti-EBV LMP-2A antibody (4E11) is an essential tool for researchers studying the mechanisms of EBV infection and associated pathologies, providing insights into the molecular interactions that facilitate viral persistence and malignancy.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

EBV LMP-2A Antibody (4E11) References:

1. Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells: implications for the pathogenesis of hemophagocytic syndrome.  |  Lay, JD., et al. 2003. J Biomed Sci. 10: 146-55. PMID: 12607539
2. Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen.  |  Sutkowski, N., et al. 2004. J Virol. 78: 7852-60. PMID: 15220463
3. Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase (hTERT) in epithelial cell lines.  |  Chen, F., et al. 2005. Int J Cancer. 113: 284-9. PMID: 15389515
4. Profiling of Epstein-Barr virus latent RNA expression in clinical specimens by gene-specific multiprimed cDNA synthesis and PCR.  |  Stevens, SJ., et al. 2005. Methods Mol Biol. 292: 27-38. PMID: 15507699
5. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells.  |  Hsiao, FC., et al. 2006. J Immunol. 177: 2056-60. PMID: 16887963
6. Epstein-Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal.  |  Engels, N., et al. 2012. Cell Commun Signal. 10: 9. PMID: 22472181
7. Skewed B cell differentiation affects lymphoid organogenesis but not T cell-mediated autoimmunity.  |  Colombo, E., et al. 2014. Clin Exp Immunol. 176: 58-65. PMID: 24325711
8. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.  |  Cho, SG., et al. 2015. Mol Ther. 23: 1401-1409. PMID: 26017177
9. The Possible Effect of B-Cell Epitopes of Epstein-Barr Virus Early Antigen, Membrane Antigen, Latent Membrane Protein-1, and -2A on Systemic Lupus Erythematosus.  |  Tu, J., et al. 2018. Front Immunol. 9: 187. PMID: 29497417
10. Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene.  |  Busson, P., et al. 1995. J Gen Virol. 76 (Pt 1): 139-45. PMID: 7844523

The preferred EBV LMP-2A antibody is EBV LMP-2A Antibody (15F9): sc-101315.